Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease

Blood. 2016 Oct 6;128(14):1896-1898. doi: 10.1182/blood-2016-06-725143. Epub 2016 Aug 17.

Authors

Eli L Diamond¹, Omar Abdel-Wahab^{2

3}, Benjamin H Durham^{3

4}, Ahmet Dogan⁴, Neval Ozkaya⁴, Lynn Brody⁵, Maria Arcila⁴, Christian Bowers⁶, Mark Fluchel⁷

Affiliations

¹ Department of Neurology.
² Leukemia Service, Department of Medicine.
³ Human Oncology and Pathogenesis Program.
⁴ Department of Pathology, and.
⁵ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
⁶ Department of Neurosurgery, University of Utah, Salt Lake City, UT; and.
⁷ Department of Pediatrics, Hematology-Oncology, University of Utah, Primary Children's Hospital, Salt Lake City, UT.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Erdheim-Chester Disease*
Humans
Interleukin 1 Receptor Antagonist Protein*

Substances

Interleukin 1 Receptor Antagonist Protein

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States